Gland Pharma shares jump 4% as Q2 profit jumps 58%, revenue rises 23% YoY
Gland Pharma shares rose 3.89% after reporting strong Q2 FY27 results, with revenue growing 23% and net profit jumping 58% year-on-year. The stock touched a 52-week high of Rs 3,345, supported by robust CDMO growth, improved margins, new product launches and increased US regulatory approvals.
Gland Pharma's shares surged 4% on Monday following the pharmaceutical firm's robust Q2 results. Net profit surged 58% year-on-year, while revenue grew 23% compared to the same period last year. The company's adjusted EBITDA margin expanded by 50%, reaching 27%. Gland Pharma's commercial pipeline expanded with the launch of four new drugs in the US market. Management expressed optimism about the company's growth trajectory, citing strong performance across its segments and continued investment in research and development.
Written by urgent.news from The Economic Times - Top News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
